Actively Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Led by Eli Lilly and Company · Updated on 2026-05-14
241
Participants Needed
29
Research Sites
383 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
CONDITIONS
Official Title
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
- Must have histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma, hormone receptor-positive HER2-negative breast cancer, HER2-positive breast cancer, triple negative breast cancer, platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma), gastric cancer (adenocarcinoma), colorectal cancer, esophageal cancer (squamous cell carcinoma or adenocarcinoma), or cholangiocarcinoma
- Must have received prior treatments as follows: for Phase 1a, pancreatic adenocarcinoma patients must have had 1 to 2 prior regimens; HR-positive HER2-negative breast cancer patients up to 5 prior lines including a CDK4/6 inhibitor; HER2-positive breast cancer patients at least 2 lines of HER2-targeted therapy including 1 antibody-drug conjugate if available; triple negative breast cancer patients at least 2 lines for metastatic disease; platinum-resistant or refractory ovarian cancer patients at least 1 platinum-based therapy; other solid tumor patients at least 1 prior systemic therapy including immunotherapy or VEGF inhibitors
- For Phase 1b, participants must have advanced or metastatic solid tumors and at least 1 prior line of therapy
- Must have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
- Measured creatinine clearance of at least 60 milliliters per minute
You will not qualify if you...
- Known active central nervous system metastases or carcinomatous meningitis
- Significant cardiovascular disease
- Prolonged corrected QTcF greater than 470 milliseconds during screening
- Evidence of ongoing and untreated urinary tract obstruction
- Previous hemi- or total-body radiation
- Previous adoptive T-cell therapy such as CAR-T or TCR therapy
- Unable to lie flat or tolerate imaging procedures including SPECT, PET, CT, or MRI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 29 locations
1
Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States, 92663
Actively Recruiting
2
Stanford University Medical Center
Stanford, California, United States, 94305
Actively Recruiting
3
Biogenix Molecular, LLC
Miami, Florida, United States, 33165
Actively Recruiting
4
Moffitt
Tampa, Florida, United States, 33612
Not Yet Recruiting
5
Indiana University (IU) School of Medicine
Indianapolis, Indiana, United States, 46202
Actively Recruiting
6
United Theranostics
Glen Burnie, Maryland, United States, 21061
Actively Recruiting
7
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
8
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
9
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Not Yet Recruiting
10
BAMF Health Inc.
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
11
Mayo Clinic - Rochester
Rochester, Minnesota, United States, 55905
Not Yet Recruiting
12
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States, 63110
Not Yet Recruiting
13
New York University (NYU) Clinical Cancer Center
New York, New York, United States, 10016
Not Yet Recruiting
14
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Not Yet Recruiting
15
Duke University Medical Center
Durham, North Carolina, United States, 27710
Actively Recruiting
16
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
17
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Not Yet Recruiting
18
Texas Oncology - DFW (Sammons CC)
Dallas, Texas, United States, 75246
Not Yet Recruiting
19
Baylor College of Medicine
Houston, Texas, United States, 77030
Not Yet Recruiting
20
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, United States, 53792
Actively Recruiting
21
Universitaetsklinikum Essen
Essen, Germany, 45147
Not Yet Recruiting
22
National Cancer Center Hospital East
Chiba, Japan, 277-8577
Not Yet Recruiting
23
Kyoto University Hospital
Kyoto, Japan, 606-8507
Not Yet Recruiting
24
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
Amsterdam, Netherlands, 1066 CX
Not Yet Recruiting
25
Amsterdam UMC - Locatie VUmc
Amsterdam, Netherlands, 1081 HV
Not Yet Recruiting
26
Erasmus MC
GE Rotterdam, Netherlands, 3015
Not Yet Recruiting
27
Maastricht University Medical Center
Maastricht, Netherlands, 6229 HX
Not Yet Recruiting
28
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Netherlands, 6525 GA
Not Yet Recruiting
29
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 3584CX
Not Yet Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here